Maria Luisa Di Silvestre, Pierluigi Gallo, Mariano Giuseppe Ippolito, Rossano Musca · 7 authors
The energy blockchain is a distributed Internet protocol for energy transactions between nodes of a power system. Recent applications of the energy blockchain in microgrids only consider the energy transactions between peers without considering the technical issues that can arise, especially when the system is islanded. One contribution of the paper is, thus, to depict a comprehensive framework of the technical and economic management of microgrids in the blockchain era, considering, for the first time, the provision of ancillary services and, in particular, of the voltage regulation service. When more PV nodes are operating in the grid, large reactive power flows may appear in the branches. In order to limit such flows, a reactive optimal power flow (R-OPF) is solved, setting the voltage at the PV buses as variables within prescribed limits. Each PV generator will thus contribute to voltage regulation, receiving a remuneration included in the transaction and certified by the blockchain technology. For showing how this system can work, a test microgrid, where some energy transactions take place, has been considered. For each transaction, the R-OPF assigns the reactive power to the PV buses. The R-OPF is solved by a glow-worm swarm optimizer. Finally, the paper proposes a method for remuneration of reactive power provision; this method, integrated into the blockchain, allows evaluating the contribution to voltage regulation and increases the transparency and cost traceability in the transactions. The application section shows the implementation of a Tendermint-based energy transaction platform integrating R-OPF and the earlier cited technical assessments.
In this study, we investigate the existence of chaos in the global cryptocurrency market. Specifically, we analyze parameters of chaotic order, nonlinearity, sensitivity to the initial conditions, monofractality, and multifractality. For this purpose, we conduct a comprehensive series of tests, including Brock–Dechert–Scheinkman (BDS) test, largest Lyapunov exponent, box-counting, and monogram analysis for fractal dimension, and multiple tests for long-range dependence (Aggregated Variances, Peng, Higuchi, R/S Analysis, and Multifractal Detrended Fluctuation Analysis (MFDFA)). All tests are performed over a variety of major cryptocurrencies: Bitcoin, Litecoin, Ethereum, and Ripple. The empirical results support the existence of chaos in the cryptocurrency market. Accordingly, cryptocurrency returns are not random and follow a chaotic order. Therefore, long term predictions are not possible, contrary to most of the discussions ongoing in the media and the public.
Purva Grover, Arpan Kumar Kar, Marijn Janssen, P. Vigneswara Ilavarasan
Although blockchain has attracted a great deal of attention from academia and industry there is a lack of studies on acceptance drivers. This study explores blockchain acceptance by mining the collective intelligence of users on Twitter. It maps blockchain user acceptance drivers to technology acceptance constructs. The analysis shows that users are attracted by security, privacy, transparency, trust and traceability aspects provided by blockchain. On Twitter more discussions on blockchain benefits than on drawbacks. Initial coin offering (ICO) is extensively discussed. The study provides guidelines for managers and concludes by presenting the limitations of the study along with future research directions.
Huma Saeed, Hassaan Malik, Umair Bashir, Aiesha Ahmad · 8 authors
Blockchain technology (BCT) has emerged in the last decade and added a lot of interest in the healthcare sector. The purpose of this systematic literature review (SLR) is to explore the potential paradigm shift in healthcare utilizing BCT. The study is compiled by reviewing research articles published in nine well-reputed venues such as IEEE Xplore, ACM Digital Library, Springs Link, Scopus, Taylor & Francis, Science Direct, PsycINFO, Ovid Medline, and MDPI between January 2016 to August 2021. A total of 1,192 research studies were identified out of which 51 articles were selected based on inclusion criteria for this SLR that presents the modern information on the recent implications and gaps in the use of BCT for enhancing the healthcare procedures. According to the outcomes, BCT is being applied to design the novel and advanced interventions to enrich the current protocol of managing, distributing, and processing clinical records and personal medical information. BCT is enduring the conceptual development in the healthcare domain, where it has summed up the substantial elements through better and enhanced efficiency, technological innovation, access control, data privacy, and security. A framework is developed to address the probable field where future researchers can add considerable value, such as data protection, system architecture, and regulatory compliance. Finally, this SLR concludes that the upcoming research can support the pervasive implementation of BCT to address the critical dilemmas related to health diagnostics, enhancing the patient healthcare process in remote monitoring or emergencies, data integrity, and avoiding fraud.
The digitization of economic activity creates new opportunities for increasing the goods production level in conditions of severe resources limitation. Significant optimization can be achieved due to, firstly, reduction the costs of transactions, and, secondly, engagement in the economic turnover of poorly low nondistributable assets (for example, real estate). The paper studies the problems regarding applicability of smart contract in economic activities at the regional and federal levels. An attempt is being made to form a decentralized system of smart contracts. Based on the component-based analysis, the key trends of this system effect on the gross output at the federal and regional levels are determined. The authors propose a quantitative assessment of the impact of each of these factors. The macroeconomic model IS-LM is used, which takes into account the impact of digitalization processes in terms of implementing the smart contracts system, on the aggregated output indicators of the economic system.
Open access
Economic and Technological Developments in Russia
Economic and Technological Systems Analysis
Digitalization and Economic Development in Agriculture
Assisting traffic control is one of the most important applications on the Internet of Vehicles (IoVs). Traffic information provided by vehicles is desired since drivers or vehicle sensors are sensitive in perceiving or detecting nuances on roads. However, the availability and privacy preservation of this information are critical while conflicted with each other in the vehicular communication. In this paper, we propose a semicentralized mode with attribute-based blockchain in IoVs to balance the tradeoff between the availability and the privacy preservation. In this mode, a method of control-by-vehicles is used to control signals of traffic lights to increase traffic efficiency. Users are grouped their attributes such as locations and directions before starting the communication. The users reach an agreement on determining a temporary signal timing by interacting with each other without leaking privacy. Final decisions are verifiable to all users, even if they have no a priori agreement and processes of consensus. The mode not only achieves the aim of privacy preservation but also supports responsibility investigation for historical agreements via ciphertext-policy attribute-based encryption (CP-ABE) and blockchain technology. Extensive experimental results demonstrated that our mode is efficient and practical.
The volume of Initial Coin Offerings (ICOs) had risen steeply with an all-time high market capitalisation of close to 1 Trillion USD in December 2017. Since then, the digital asset market has slumped, retreating to approximately 200 Billion USD by mid-2018. Stakeholders of the crypto industry have pondered the reasons for this retrenchment and are increasingly focusing on the notion that many ICOs could be scams. A recent industry study even went as far to claim that 80% of all ICOs are indeed scams. In this paper, we investigate the question whether these scams are as common as claimed. We do so by first defining what a scam is and secondly, by drawing on empirical data to assess the number of cases fitting such a definition. Building on Principal Agent Theory and based on the statistical analysis of our empirical data set we attempt to establish the current state of affairs with regards to scams in the cryptocurrency world. The results of our study divert from salient beliefs.
We performed the first systematic study of a new attack on Ethereum that steals cryptocurrencies. The attack is due to the unprotected JSON-RPC endpoints existed in Ethereum nodes that could be exploited by attackers to transfer the Ether and ERC20 tokens to attackers-controlled accounts. This study aims to shed light on the attack, including malicious behaviors and profits of attackers. Specifically, we first designed and implemented a honeypot that could capture real attacks in the wild. We then deployed the honeypot and reported results of the collected data in a period of six months. In total, our system captured more than 308 million requests from 1,072 distinct IP addresses. We further grouped attackers into 36 groups with 59 distinct Ethereum accounts. Among them, attackers of 34 groups were stealing the Ether, while other 2 groups were targeting ERC20 tokens. The further behavior analysis showed that attackers were following a three-steps pattern to steal the Ether. Moreover, we observed an interesting type of transaction called zero gas transaction, which has been leveraged by attackers to steal ERC20 tokens. At last, we estimated the overall profits of attackers. To engage the whole community, the dataset of captured attacks is released on https://github.com/zjuicsr/eth-honey.
:I analyze cryptocurrency ecosystems with Elinor Ostrom’s meta-framework for self-governance. I conclude that Bitcoin falls short in its self-governing ambitions, while cryptocurrency software protocols and blockchain technologies have potentialities within “permissioned” peer-to-peer private or hybrid networks. However, regulation and supervision by trusted third parties are required.
Sahil Garg, Kuljeet Kaur, Georges Kaddoum, François Gagnon · 5 authors
Vehicle-to-grid (V2G) networks have emerged as a new technology in modern electric power transmission networks. It allows bi-directional flow of communication and electricity between electric vehicles (EVs) and the Smart Grid (SG), in order to provide more sophisticated energy trading. However, due to the involvement of a huge amount of trading data and the presence of untrusted entities in the visiting networks, the underlying V2G infrastructure suffers from various security and privacy challenges. Although, several solutions have been proposed in the literature to address these problems, issues like lack of mutual authentication and anonymity, incapability to protect against several attack vectors, generation of huge overhead, and dependency on centralized infrastructures make security and privacy issues even more challenging. To address the above mentioned problems, in this paper, we propose a blockchain oriented hierarchical authentication mechanism for rewarding EVs. The overall process is broadly classified into the following phases: 1) System Initialization, 2) Registration, 3) Hierarchical Mutual Authentication, and 4) Consensus; wherein blockchain's distributed ledger has been employed for transaction execution in distributed V2G environments while Elliptic curve cryptography (ECC) has been used for hierarchical authentication. The designed hierarchical authentication mechanism has been employed to preserve the anonymity of EVs and support mutual authentication between EVs, charging stations (CSs) and the central aggregator (CAG). Additionally, it also supports minimal communicational and computational overheads on resource constrained EVs. Further, formal security verification of the proposed scheme on widely accepted Automated Validation of Internet Security Protocols and Applications (AVISPA) tool validates its safeness against different security attacks.
Kuljeet Kaur, Sahil Garg, Georges Kaddoum, François Gagnon · 5 authors
With the increasing development of advanced communication technologies, vehicles are becoming smarter and more connected. Due to the tremendous growth of various vehicular applications, a huge amount of data is generated through advanced on-board devices and is deemed critical to improve driving safety and enhance vehicular services. However, cloud based models often fall short in applications where latency and mobility are critical. In order to fully realize the potential of vehicular networks, the challenges of efficient communication and computation need to be addressed. In this direction, vehicular fog computing (VFC) has emerged which extends the concept of fog computing to conventional vehicular networks. It is a geographically distributed paradigm that has the potential to conduct time-critical and data-intensive tasks by pushing intelligence (i.e. computing resources, storage, and application services) in the vicinity of end vehicles. However secure and reliable transmission are of significant importance in highly-mobile vehicular networks in order to ensure the optimal Quality of Service (QoS). In this direction, several authentication mechanisms have been proposed in the literature but most of them are found unfit due to absence of decentralization, anonymity, and trust characteristics. Thus, an effective cross-datacenter authentication and key-exchange scheme based on blockchain and elliptic curve cryptography (ECC) is proposed in this paper. Here, the distributed ledger of blockchain is used for maintaining the network information while the highly secure ECC is employed for mutual authentication between vehicles and road side units (RSUs). Additionally, the proposed scheme is lightweight and scalable for the considered VFC setup. The performance evaluation results against the existing state-of-the-art reveal that the proposed scheme accomplishes enhanced security features with reduced computational and communicational overheads. Further, its extensive evaluation on the widely applicable Automated Validation of Internet Security Protocols and Applications (AVISPA) tool guarantee its safeness against different attack vectors.
The main principles of blockchain operation and its main advantages of efficiency increase of investment and construction activity (ICA) participants' interaction are described in this article. Blockchain process operation principles in a technical sense are stated. Practical examples of efficiency increase of ICA participants' interaction with the use of blockchain process in Russia and abroad are given. The main trends and results of blockchain use in construction domain are systematised. Potential of blockchain process use in development of the system of ICA participants' interaction is described. Specific features and advantages of blockchain use in construction domain are highlighted. The main problems requiring improvement of normative and methodical base while developing blockchain within ICA participants' interaction are analysed. The article gives a review of blockchain influence on improvement of the process of ICA participants' interaction.
The atmosphere at the 5th Annual Immuno-Oncology 360° (IO360°) Conference, which took place on February 6–8 at the Crowne Plaza Times Square in New York City, was truly collaborative. Co-chaired by Axel Hoos, MD, PhD (GSK), James Gulley, MD, PhD (National Cancer Institute [NCI]), and Andrew Baum, MD (Citi), the conference featured almost 100 speakers and 10 plenary sessions, including 4 keynote talks and 7 panel discussions. More than 400 attendees representing the pharma, biotech, academic, regulatory, and private investment communities gathered to discuss the rapid advancement in scientific, clinical, and business developments in IO, with the goal of accelerating the development of new therapeutics for patients. Over 350 partnering meetings took place over the 3-day conference.“360 degrees means we really want to speak to all stakeholders,” stated Dr. Hoos. The meeting is structured for the scientists to bring their most promising next-generation mechanisms that will help address these challenges. However, it is also important to look at therapies that haven't worked, so we don't repeat the same challenges of the past, he noted. “But IO360° is not just the science, it's about the entire ecosystem in which the science exists, and that includes the patients and those that provide the funding to make the science happen.”Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center, opened the meeting with a keynote, Chimeric Antigen Receptor (CAR) - T Cell Therapy and the CD19 Paradigm. With two CD19 CAR-T cells (CAR Ts) approved in 2017, Dr. Sadelain identified three new directions being taken to optimize CAR T therapy and develop next-generation CAR Ts. The first is addressing exhaustion (loss of functionality) using genome engineering at a carefully select locus (TRAC) to create more potent CAR Ts and incorporating new designs that modify the activating portion of the CAR and balance rapid expansion and retained memory (1XX CAR). The second is gaining insight into the pathophysiology of cytokine release syndrome, including CAR T–macrophage interactions, to try and reduce toxicity. The third is employing new strategies for circumventing antigen escape, such as use of radiosensitization and combinatorial targeting.The Discovery and Preclinical Science plenary focused on strategies being investigated to modify the tumor microenvironment and address limitations of patient-sourced therapies. According to the plenary chair, Ronald Herbst, PhD, “we are all excited about the potential for immunotherapy for patients with cancer, but many patients don't respond to checkpoint inhibitors.” Part of the problem is explained by the fact that “immune contexture varies within and across tumor types, and so-called ‘hot’ versus ‘cold’ tumors,” he noted. In order to increase the efficacy of immunotherapy, a number of areas are actively being targeted, including antigen presentation, innate mechanisms of activation, the tumor microenvironment, and overcoming immunosuppression.A variety of cells, growth factors, and cytokines in the tumor microenvironment play a pivotal role in whether or not immunotherapy is effective. Various strategies are being employed that attempt to modify the tumor microenvironment to overcome immunosuppressive mechanisms, such as blocking adenosine with an anti-CD73 monoclonal antibody (oleclumab, Medimmune) or an A2A receptor antagonist (CPI-144, Corvus), or inhibiting the IDO (indoleamine 2,3-dioxygenase) pathway (indoximod, NewLink Genetics). Other strategies are being employed to enhance the efficacy of cytokines to augment the expansion and activation of T cells, such as engineering enhanced versions of growth factors such as interleukin-2 (IL-2; NKTR-214, Nektar, and MDNA109, Medicenna) and IL-10 (pegilodecakin, ARMO). For example, pegilodecakin, a long-acting pegylated form of IL-10, induces hallmarks of CD8+ T cell immunity in cancer patients. According to Aung Naing, MD, and Martin Oft, MD, pegilodecakin demonstrated clinical benefit in studies as a single agent and in combination with both chemotherapy and checkpoint inhibitors across several tumor types. The agent is currently being investigated in a Phase 3 trial in metastatic pancreatic cancer.Off-the-shelf hematopoietic cell products are being developed to address some of the limitations of patient-sourced cell therapies, such as heterogeneity, single-patient manufacturing, need for sufficient cells, extended production time, and cost. For example, engineered CAR natural killer cells, derived from induced pluripotent stem cells, are being developed that incorporate several individual components that together help to enhance persistence and antitumor efficacy (FT596, Fate Therapeutics). Multicombinatorial strategies such as this may be key in reigniting the endogenous immune system and improving efficacy in solid tumor space.Genentech's Priti Hegde, PhD, opened the Translational Science and Emerging Biomarkers plenary, part 1, with a keynote, Biomarker Signaling: Turning Cold Tumors Hot. Individual cancer types can be characterized along the tumor immunity continuum based on immune phenotype (i.e. inflamed or noninflamed) and tumor mutational burden (TMB). How can we generate an immune response signal in noninflamed tumors when most do not achieve the TMB threshold that selects for benefit? Dr. Hedge highlighted two approaches: adaptive immunity, which has the potential to drive memory response, and synthetic immunity, which has the potential to sustain efficacy and drive log kill. An example of an adaptive immunity approach is neoantigen-specific T-cell therapy, in which there are limited but encouraging data demonstrating its ability to promote adaptive immunity in noninflamed tumors. Synthetic immunity approaches include engineered T cells (e.g. NY-ESO SPEAR T cells [GSK/Adaptimmune], BMCA CAR Ts) and bi-specific biologics (e.g. antibodies, BITEs® [Amgen], ImmTAC® [Immunocore]), in which there is a proof of concept that these approaches are feasible in solid tumors and checkpoint inhibitor-refractory hematologic malignancies.One may also need to address the underlying biology to turn cold tumors hot. According to Dr. Hegde, the future of immunotherapy may be highly personalized, and one will need to look at a variety of markers in biopsy specimens using a variety of techniques. This will only be possible if we have: (1) a tissue-conserving, regulatory-grade decentralized platform to be able to run all of these assays in trials and (2) trial designs and statistical analysis plans that enable diagnostic signal-seeking validation and a path for registration.The remainder of the plenary reported on translational data and evolving biomarkers and applications to help support decision-making for IO drug development.Negative results from the Phase 3 study of the therapeutic prostate cancer vaccine PROSTVAC (Bavarian Nordic) show that a combinatorial approach may be needed with vaccines. Similarly, oncolytic viruses may need multiple transgenes and mechanisms to reverse complex immunosuppressive microenvironments. To address this issue, T-Stealth™ oncolytic viruses (BeneVir) can incorporate multiple genes, evade clearance by the innate and adaptive immune systems, and be combined with other drugs and IO agents.With the increasing need for biomarker support, the clinical trial laboratory reality in the IO space is complex. Patrice Hugo, PhD (Q2 Solutions), summarized important features to consider when selecting a lab partner for drug development. Key strategies to successfully introduce innovation in the clinical trial lab space include joint review of pros and cons of technologies, consideration of joint investments, performing Phase 1 specialized testing in niche labs/academic settings with transfer to a central lab, and discussion and planning for regulatory requirements.Advances in positron emission tomography (PET) imaging and radiomics provide a quantitative, noninvasive way to assess the dynamic changes of the immune system. For example, CD8 PET (Imaging Endpoints) may help distinguish between hot and cold tumors and address fundamental questions regarding the role of CD8 cells in the tumor microenvironment.Other unique biomarkers and applications under investigation include MultiOmyx™ (NeoGenomics), a proprietary multi “omic” technology that enables detection and visualization of up to 60 biomarkers on a single slide; immunosequencing (immunoSEQ, Adaptive Biotechnologies), a clinical diagnostic for monitoring clonal expansion and predicting/evaluating response to therapy that can also be used in combination with cellular immunology and computational biology (Multiplexed Identification of T cell Receptor Antigen [MIRA] assay, Adaptive Biotechnologies) to map T-cell receptors; and CANscript™ (Mitra), a personalized ex vivo histoculture approach that can be used to evaluate drug-induced modulation of the tumor microenvironment and predict clinical performance.The IO Novel Technologies and Innovative Solutions plenary showcased companies that have technologies and solutions that will help stakeholders in the IO field advance developments for cancer therapeutics. Presenters included Advaxis, Bioxcel Therapeutics, IAG, Provecs Medical, Rgenix, and Sensei Bio.Andrew Baum, MD (Citi), opened the Financial and Commercial Implications plenary with a keynote, Evaluation and Forecast of the IO Space. He started off by discussing key questions on health-care investors' minds. According to Dr. Baum, “what investors don't like very much about IO is that the technology cycles are short, so you can go from here to zero very quickly very easily.” He cited ipilimumab and the fact that it was quickly eclipsed by anti-PD (L)-1 agents. Another issue is the “paradox of choice,” as there are so many different modalities. “It's almost overwhelming,” he noted, “especially for someone that doesn't have a deep scientific background to interpret a Phase one trial.” Other questions involve primary and secondary resistance, cell therapy manufacturing constraints, minimizing/managing toxicity, and financial toxicity. However, despite these questions, “the good news is the amount of capital, the enthusiasm, and the scientific advancement all mean that we're going to make huge strides in IO, I have no doubt.”Dr. Baum stressed the importance of learning from historic disappointments and noted that we need better biomarkers, better trials, and patience so that the benefits can be extended to more patients. He ended his presentation with a slide showing Citi's top 10 novel IO targets for 2020, in which IL-2/IL-15 took the top spot.Khalil Barrage (Invus) agreed that the IO revolution has led to unprecedented investor enthusiasm for oncology, unlocking massive commercial opportunities. However, the discovery of checkpoints and their curative potential has led to hype in IO drug discovery, resulting in risky behavior. In addition, the flood of capital has lowered potential returns and there are a lot of IO agents in development with poorly validated rationale. As a result, Invus' approach to investing incorporates strategies such as diversification, selectivity, exploring synergistic opportunities, investing where innovation is happening, paying a premium for validated approaches when warranted, and assessing reimbursement.The plenary concluded with a panel discussion on monetizing science: the preparation of an IPO, straight licensing with the transition to a public company, and decision-making on prioritization within portfolios. Key takeaways included strategies for building out scientific and executive talent, the importance of having a scientific advisory board to test out the research, and being prepared to be a public company.The Trends and Collaborations plenary featured presentations by three major industry media companies in the IO field, which discussed new trends and their effect on the investment landscape.BioCentury analyzes IO trends at recent medical meetings using machine learning, began Simone Fishburn, PhD, VP, and Executive Editor. Despite the huge focus on PD (L)-1, academics and companies are aggressively looking for, and finding new targets, with LAG3 topping the list in company oncology pipelines in 2019. CAR T activity is moving into solid tumors, with new constructs and multiple tumor antigens targeted. Immunometabolism and tumor mutation burden are hot topics. Funding for IO start-ups is outstripping other areas, both inside and outside oncology, drawing traditional and corporate investors.According to John D. Carroll (Endpoints News), these trends are supported by global data published by the Cancer Research Institute, which show that there were 3394 IO agents representing 417 targets in the pipeline in 2018, representing a 67% increase over 2017.How are these trends affecting the investment landscape? According to Jeff Bockman, PhD (Cello Health BioConsulting), IO dominates oncology growth, but not sales. Moreover, although IO deals have shown evidence of slowing, whether due to maturation, saturation, or fatigue, and oncology and IO investments remain robust.The Business Development plenary, hosted by Solebury Trout, included panel discussions on partnering, fundraising, and rational investing. The first panel discussed IO partnering strategies from the viewpoint of pharma and academia. According to Dr. Hoos, who the partnering in this space have but there has much and is only that companies have started their unique which will a partnering the for is tumor and the and the companies on the panel and there to be both and with some moving from and on those that can IO and agents are being by most in the and are to play which was for and discussed in the IO space and a number of For example, the panel stressed the importance of at and and on key and as a private on their ecosystem their investors with in the past, key to their than at with the top at the with key the of and companies introduce than need to so that can panel focused on IO investment investors this an time, with a future for many modalities. However, the massive of data is it to to to from a The investors on the panel on a variety of such as the of and whether the data support a or whether an agent has a or has a niche in the IO important is a in their and their to plenary ended with a with of by Solebury Trout, the discussion focused on in the company, with a an For companies looking for highlighted the fact that as a and stressed the need to and where are are some very so both and in to a with a can try and to more like in As industry are companies can be quickly with limited capital, like companies have in the began with a keynote, to led by and MD, of of According to Dr. we are at an in it has from one to has the and of tumor types, agents and trials are and there is an to use to enable to of trials are the way new therapies are developed for cancer, make better and more personalized The of are testing drugs where most (i.e. the order of therapy to about response in the of building an to evaluate drugs and using imaging and biomarker and being by is a platform trial for of biopsy is used to assess and imaging and adaptive The and the are structured to enable and release of agents the The primary is response which is a highly of and and is in biomarker The from biomarker and is to drug to Dr. we want innovation to we have to The focus of new drug development be a a from of metastatic to is a huge is also a huge goal of is to of patients to with and of therapy based on Dr. ended with one of for drug from finding out which drug be to the with two The first Science and Emerging Biomarkers Part was led by PhD, of and to focus on biology and to help predict to Technologies discussed included to enhance antibody therapeutics mechanisms of to immune the for biomarker discovery a and a receptor in second for IO was led by of and was for clinical trial who to it to an IO clinical discussed included an clinical trial study a complex Phase 1 trial in IO and clinical trial for The ended in a panel discussion on the challenges with IO data and to advance to PhD, at the and (i.e. may not the clinical benefit of IO agents. As a result, trends include the use of immune response machine learning to the of imaging and new techniques. The IO plenary up the with a discussion of novel imaging are unique challenges with the use of response at IO clinical as a of complex According to some of these challenges can be by the and of response and including a of in the can be by the use of and and analysis and PhD are being used in with to more from to as as better between and such as the CD8 PET discussed is also an evolving Similarly, imaging using PET an to assess all of a tumors for with a single PET and assess use of a novel three opened with the of with cancer, cancer 10 as metastatic chemotherapy and therapies, and of an immunotherapy trial at the The the that cancer, and those cells in the an of the cells and the cancer has the of being the first to be of metastatic cancer a of to to from in the concluded with some to patients who be in the same the same to with cancer or out as much as you can about to a cancer to to not just one of therapy but several of out about clinical trials and whether you can in The is out there and you as try and on the was a panel discussion on to IO in a The are to but be and and the of a tumor to be want to if the tumor has by the adaptive immune is it by T cells if do have an immunosuppressive factors are in the tumor However, are an important the is the of the cell types are but also and able to look in the is but it doesn't provide all the can all these be with a new plenary for Cell According to Dr. Gulley, therapy has the to on the of cancer there is activity in hematologic but it's is needed to achieve the same effect in solid tumors, so this is where there is much The is to was in studies but the benefit to a of patients. The new technologies and targets discussed in this plenary to do just technology to a T cells their However, in the of approved CAR are According to MD of this as a of of and of He cited a where CD19 in a single cell led to by the CD19 which may have important for manufacturing and other cell therapies. For and the can be with a CAR T or it can be with a new of CAR that the SPEAR are an engineered T-cell of cells that are to a that a antigen in many technology an over CAR T therapy in that it to both and results have in a cancer for which there are no therapies the of noted products a number of over CAR Ts. CAR Ts Chimeric Antigen Receptor developed using the platform are being investigated in and multiple The is to multiple to create T cells with such as the ability to or overcome may an over other therapies in solid tumors in that multiple tumor antigens and there is a of or The technology used to develop the that has and of efficacy have in and the for the has from to to and the is a therapies have the potential to enhance CAR T activity in solid tumors. combination strategies consider both and can be used to enhance cell and and factors in the tumor microenvironment, or and plenary ended with a panel discussion on and clinical to IO therapeutics that will to more and therapies. of the strategies discussed were including a to and products and addressing antigen with or combination In order to we need to address like the when moving from in to the clinical as as cell and the used to create the may the cells, manufacturing and we need to cell therapies so that more patients will have conference concluded with the IO Development plenary, which discussed recent IO clinical The plenary began with an of data for the activity has demonstrated in more than cancer types. The agent has across more than including in is moving into the of therapy, and next-generation biomarkers are to help promising were also for a a and combination immunotherapy and the tumor receptor has to more benefit in Dr. Hoos. However, there is a lot of As a result, “we need to new to the benefit PD Cell therapy has really to the of engineered and we are to the benefit from to solid tumors and overcoming the such as T-cell that in the for patients is
A. Timofeev, O. Lebedinskaya, Roman Veynberg, A. A. Grigorev
This article presents prospects of the development of cryptocurrency in Russia, examines the principles of the operation of Bitcoin as main currency nowadays and its application in the real economic sector. Identifies and substantiates the advantages and disadvantages of this technology, as a result, the degree of influence of cryptocurrency and the consequences of its usage in the Russian economy. At present, over 1000 types of cryptocurrencies exist. In this paper, two of them are analyzed: the first cryptocurrency, the leader with the stabilized volatility and price: Bitcoin, and rather a new application for cryptocurrency which was skyrocketed as the second world popular: Ethereum. In this research paper we set an objective to compare Bitcoin and Ethereum, determine problems of cryptocurrency market in Russia and the prospects for development of their usage. In addition, authors are describing history of the research subject and trends to develop: from Bitcoin to Ethereum evolution.
Blockchain technique, with the novelties of decentralization, smart contract, security and cooperative autonomy, is expected to play great effects on promoting the development of energy local networks (ELNs). This paper presents an automated demand response (ADR) framework for decentralized scheduling and secure peer-to-peer (P2P) trading among energy storage systems in ELNs. Different from most existing works that trade electricity over long distances and through complex meshes, this proposed work performs decentralized and automated demand response through energy sharing of P2P executors. We explore for the first time the benefits of a promising blockchain to conduct the overall ADR framework and increase the P2P trading security. To achieve decentralized scheduling without relying on a central entity, a price-incentive noncooperative game theoretic model is introduced to produce equilibrium solutions for energy storage systems. Moreover, we develop a schedulable ability evaluation system to match trading pairs involving buying and selling nodes. On this basis, a state-machine-driven smart contract mechanism is built to realize P2P trading without reliance on a trusted third party. To illustrate the implementation details of the ADR method, a distributed algorithm is designed. Case studies are provided to verify the effectiveness of the proposed method.
Retrieving a set of 143 cryptocurrencies for a sample spanning 2014–2018, we investigate the popular momentum strategy implemented in the cryptocurrency market. Contrary to earlier studies our findings do not indicate any evidence of significant momentum payoffs, supporting the view that the cryptocurrency market is far more efficient than suggested in earlier studies.
High-value derivatives contracts require substantial legal protection and often utilise standardised legal documentation provided by the International Swaps and Derivatives Association (ISDA). Smart Derivatives Contracts aim to automate many aspects of high-value contracts, including automation of the provisions of the ISDA legal documentation. Here we investigate how the ISDA Master Agreement may affect the automation of payments and deliveries: we provide a framework for understanding how high-value derivatives contracts are structured at different levels, in terms of both the legal documentation and the workflow; we explain issues relating to how the smart contract code processes payments-related and deliveries-related events; and we discuss the extent to which these are amenable to automation.
The EPCglobal Network is a computer network used to share product data between trading partners. The EPC Information Services (EPCIS) is an event record repository that allows disparate applications to access and query for data both within and across enterprises. Ultimately, this data sharing is aimed at enabling participants in the EPCglobal Network to gain a shared view of the disposition of EPC-bearing objects within a relevant business context [1].Despite the potential benefits, enterprises are reluctant to integrate into the EPCglobal Network due to the financial and manpower resources required to set up, operate and maintain the EPCIS and to adopt the standards. Issues like security, computation and storage overheads would also have to be managed. To solve the problem, this paper advocates a blockchain solution using Hyperledger Fabric to serve as a shared EPCIS across trading partners. The blockchain can be queried directly to facilitate information sharing subjected to access control rules. It also adheres to the EPCglobal Network standards. This approach provides several important benefits including eliminating the need for enterprises to maintain their own EPCIS while still being able to participate and benefit from the network. As the blockchain can be queried directly, the provision of EPC Discovery Services (EPCDS) may also be unnecessary. To explore this idea, we constructed a prototype using Hyperledger Composer and Hyperledger Fabric while adhering to the data elements, structures and formats as stated in the standards to ensure interoperability with existing architecture both upstream and downstream.
In economic activities, there are massive contracts, transactions, and payments. The consistency, integrity, and security of these important transaction data are crucial. The application of blockchain technology in document certification, asset trading and payment reconciliation, solves the security vulnerabilities existing in traditional technical solutions, optimizes business models, improves efficiency, ensures security, and enhances core competitiveness.
Morteza Dabbaghjamanesh, Boyu Wang, Shahab Mehraeen, Jie Zhang · 5 authors
This paper proposes a novel framework for privacy and security enhancement of power trading in the networked microgrids (MGs) based on the blockchain-enabled Internet of Things (IoT) approach. Utilizing the blockchain-enabled IoT technology in the power trading of the network MGs can potentially lead to some significant advantages such as fewer system risks, mitigate financial fraud, and less the operational cost. A newly stochastic framework based on the unscented transform (UT) is employed to model the uncertainties of renewable energy resources and hourly load demand. Consequently, the proposed framework is tested on the network MG containing residential MG (as a non-crucial load), commercial MG (as an intermediate level load), and hospital MG (as a crucial load), to validate the effectiveness and high performance of the proposed technique.
The blockchain technology is complex and involves a wide range of fields, which leads to the lack of uniform specifications for the development of blockchain applications. Although blockchain used to be divided according to the decentralized degree by some organizations, which are difficult to give developers specific guidance and results. To this end, this paper proposed a feature-oriented classification method of blockchain applications based on the analysis and comparison of current typical blockchain applications and frameworks, including digital currency blockchain, development platform blockchain, decentralized application and extended blockchain, helping developer create blockchain applications of a targeted manner and clarifying the functional architecture of different types of above various blockchain applications. Finally, the above classification method has been verified by the analysis of an extended blockchain.